MedTrace Logo

Feasibility of Using Surplus qFIT Samples to Investigate the Gut Microbiota.

NCT06100549 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 116

Last updated 2026-02-12

No results posted yet for this study

Summary

The Scottish Bowel Screening Programme is an enormous potential research resource; half a million people in Scotland do their bowel screening test each year. If we could obtain meaningful data on the gut microbiota in these individuals, many clinical questions could be answered using nested case-control studies relating gut microbiota profiles to cancer, obesity, cardiovascular and metabolic diseases and Alzheimer's disease. As individuals are screened from age 50 to 74 years, there would also be excellent opportunities for longer-term longitudinal studies.

Since 2017, the bowel screening programme has used qFIT testing for faecal haemoglobin. Patients collect a tiny (2 miligram) sample of their faeces into 2 mililiter of buffer but only approximately 6 microliter is required for testing. The goal of this study is to investigate whether the large number of patients' samples available from the National Bowel Screening Programme could be used in future gut microbiome studies using the leftover faeces in buffer in the qFIT tests.

Conditions

  • Gut Microbiota

Interventions

OTHER

No intervention

No intervention will be provided.

Sponsors & Collaborators

  • NHS Grampian

    collaborator OTHER_GOV

  • University of Aberdeen

    lead OTHER

Principal Investigators

  • Anne E Kiltie, Prof · University of Aberdeen

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-28
Primary Completion
2024-02-12
Completion
2024-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06100549 on ClinicalTrials.gov